Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA

J Clin Invest. 2000 Mar;105(6):777-82. doi: 10.1172/JCI9079.

Abstract

Effective therapeutic interventions and clinical care of adults infected with HIV-1 require an understanding of factors that influence time of response to antiretroviral therapy. We have studied a cohort of 118 HIV-1-infected subjects naive to antiretroviral therapy and have correlated the time of response to treatment with a series of virological and immunological measures, including levels of viral load in blood and lymph node, percent of CD4 T cells in lymph nodes, and CD4 T-cell count in blood at study entry. Suppression of viremia below the limit of detection, 50 HIV-1 RNA copies/mL of plasma, served as a benchmark for a successful virological response. We employed these correlations to predict the length of treatment required to attain a virological response in each patient. Baseline plasma viremia emerged as the factor most tightly correlated with the duration of treatment required, allowing us to estimate the required time as a function of this one measure.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / administration & dosage*
  • Anti-HIV Agents / pharmacology
  • Anti-HIV Agents / therapeutic use
  • CD4 Lymphocyte Count / drug effects
  • CD4-Positive T-Lymphocytes / pathology
  • Carbamates
  • Cohort Studies
  • Dideoxynucleosides / administration & dosage
  • Dideoxynucleosides / pharmacology
  • Dideoxynucleosides / therapeutic use
  • Furans
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV Infections / virology
  • HIV Protease Inhibitors / administration & dosage
  • HIV Protease Inhibitors / pharmacology
  • HIV Protease Inhibitors / therapeutic use
  • HIV Reverse Transcriptase / antagonists & inhibitors
  • HIV-1 / isolation & purification*
  • Humans
  • Lamivudine / administration & dosage
  • Lamivudine / pharmacology
  • Lamivudine / therapeutic use
  • Lymph Nodes / virology
  • Nelfinavir / administration & dosage
  • Nelfinavir / pharmacology
  • Nelfinavir / therapeutic use
  • RNA, Viral / blood*
  • Reverse Transcriptase Inhibitors / administration & dosage
  • Reverse Transcriptase Inhibitors / pharmacology
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Saquinavir / administration & dosage
  • Saquinavir / pharmacology
  • Saquinavir / therapeutic use
  • Stavudine / administration & dosage
  • Stavudine / pharmacology
  • Stavudine / therapeutic use
  • Sulfonamides / administration & dosage
  • Sulfonamides / pharmacology
  • Sulfonamides / therapeutic use
  • Time Factors
  • Viral Load*
  • Viremia / drug therapy*
  • Zidovudine / administration & dosage
  • Zidovudine / pharmacology
  • Zidovudine / therapeutic use

Substances

  • Anti-HIV Agents
  • Carbamates
  • Dideoxynucleosides
  • Furans
  • HIV Protease Inhibitors
  • RNA, Viral
  • Reverse Transcriptase Inhibitors
  • Sulfonamides
  • Lamivudine
  • Zidovudine
  • amprenavir
  • Stavudine
  • HIV Reverse Transcriptase
  • Nelfinavir
  • Saquinavir
  • abacavir